KK Kirchner, JS Wagener, TZ Khan, SC Copenhaver and FJ Accurso
Department of Pediatrics, University of Colorado School of Medicine, The Children's Hospital, Denver, USA.

Airway inflammation in children younger than 5 yr of age is difficult to assess, particularly in patients with cystic fibrosis (CF). Furthermore, determining responses to therapies is often subjective in infants, especially those with CF. To determine whether airway DNA levels could be used as an index of airway inflammation, we measured DNA levels in bronchoalveolar lavage fluid (BALF), using a Hoechst dye- binding assay. BALF DNA levels and neutrophils from 16 infants with CF were compared with levels obtained from seven older CF patients and nine control children who underwent bronchoalveolar lavage for evaluation of other pulmonary diseases. BALF DNA was increased in both infants (3.2 +/- 0.7 microg/ml) and older patients with CF (5.4 +/- 0.9 microg/ml) compared with the controls (0.7 +/- 0.2 microg/ml) (mean +/- SEM). BALF DNA levels were not significantly different between infants and older patients with CF. BALF neutrophil counts in CF patients were significantly higher than in controls. Furthermore, BALF DNA levels and total neutrophil counts in infants with CF correlated positively with one another. We conclude that: (1) DNA levels were easily quantifiable in BALF of young children; (2) DNA levels in BALF from CF patients were greater than in a group of children with other pulmonary diseases, and that in some infants with CF, BALF DNA levels were equivalent to those of much older patients with CF; (3) DNA levels in BALF correlate with BALF neutrophil number, an index of inflammation; and (4) some infants with CF have increased levels of DNA in BALF, which may justify a clinical trial of aerosolized rhDNase in this population.

This article has been cited by other articles:

				S. M. Bianchi, L. R. Prince, K. McPhillips, L. Allen, H. M. Marriott, G. W. Taylor, P. G. Hellewell, I. Sabroe, D. H. Dockrell, P. W. Henson, et al. Impairment of Apoptotic Cell Engulfment by Pyocyanin, a Toxic Metabolite of Pseudomonas aeruginosa Am. J. Respir. Crit. Care Med., January 1, 2008; 177(1): 35 - 43. [Abstract] [Full Text] [PDF]

				S. D. Davis, L. A. Fordham, A. S. Brody, T. L. Noah, G. Z. Retsch-Bogart, B. F. Qaqish, B. C. Yankaskas, R. C. Johnson, and M. W. Leigh Computed Tomography Reflects Lower Airway Inflammation and Tracks Changes in Early Cystic Fibrosis Am. J. Respir. Crit. Care Med., May 1, 2007; 175(9): 943 - 950. [Abstract] [Full Text] [PDF]

				M. S. Stalvey, C. Muller, D. A. Schatz, C. H. Wasserfall, M. L. Campbell-Thompson, D. W. Theriaque, T. R. Flotte, and M. A. Atkinson Cystic Fibrosis Transmembrane Conductance Regulator Deficiency Exacerbates Islet Cell Dysfunction After {beta}-Cell Injury. Diabetes, July 1, 2006; 55(7): 1939 - 1945. [Abstract] [Full Text] [PDF]

				M. A. Delgado, J. F. Poschet, and V. Deretic Nonclassical Pathway of Pseudomonas aeruginosa DNA-Induced Interleukin-8 Secretion in Cystic Fibrosis Airway Epithelial Cells. Infect. Immun., May 1, 2006; 74(5): 2975 - 2984. [Abstract] [Full Text] [PDF]

				R. Tirouvanziam, C. K. Conrad, T. Bottiglieri, L. A. Herzenberg, R. B. Moss, and L. A. Herzenberg High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis PNAS, March 21, 2006; 103(12): 4628 - 4633. [Abstract] [Full Text] [PDF]

				T. J. Moraes, J. Plumb, R. Martin, E. Vachon, V. Cherepanov, A. Koh, C. Loeve, J. Jongstra-Bilen, J. H. Zurawska, J. V. Kus, et al. Abnormalities in the Pulmonary Innate Immune System in Cystic Fibrosis Am. J. Respir. Cell Mol. Biol., March 1, 2006; 34(3): 364 - 374. [Abstract] [Full Text] [PDF]

				W. W. Busse, A. Wanner, K. Adams, H. Y. Reynolds, M. Castro, B. Chowdhury, M. Kraft, R. J. Levine, S. P. Peters, and E. J. Sullivan Investigative Bronchoprovocation and Bronchoscopy in Airway Diseases Am. J. Respir. Crit. Care Med., October 1, 2005; 172(7): 807 - 816. [Abstract] [Full Text] [PDF]

				K. Paul, E. Rietschel, M. Ballmann, M. Griese, D. Worlitzsch, J. Shute, C. Chen, T. Schink, G. Doring, S. van Koningsbruggen, et al. Effect of Treatment with Dornase Alpha on Airway Inflammation in Patients with Cystic Fibrosis Am. J. Respir. Crit. Care Med., March 15, 2004; 169(6): 719 - 725. [Abstract] [Full Text] [PDF]

				A. J. Jesaitis, M. J. Franklin, D. Berglund, M. Sasaki, C. I. Lord, J. B. Bleazard, J. E. Duffy, H. Beyenal, and Z. Lewandowski Compromised Host Defense on Pseudomonas aeruginosa Biofilms: Characterization of Neutrophil and Biofilm Interactions J. Immunol., October 15, 2003; 171(8): 4329 - 4339. [Abstract] [Full Text] [PDF]

				T. E. Robinson, A. N. Leung, W. H. Northway, F. G. Blankenberg, F. P. Chan, D. A. Bloch, T. H. Holmes, and R. B. Moss Composite Spirometric-Computed Tomography Outcome Measure in Early Cystic Fibrosis Lung Disease Am. J. Respir. Crit. Care Med., September 1, 2003; 168(5): 588 - 593. [Abstract] [Full Text] [PDF]

				J. B. Lyczak, C. L. Cannon, and G. B. Pier Lung Infections Associated with Cystic Fibrosis Clin. Microbiol. Rev., April 1, 2002; 15(2): 194 - 222. [Abstract] [Full Text] [PDF]

				C. J. DAKIN, A. H. NUMA, H. WANG, J. R. MORTON, C. C. VERTZYAS, and R. L. HENRY Inflammation, Infection, and Pulmonary Function in Infants and Young Children with Cystic Fibrosis Am. J. Respir. Crit. Care Med., April 1, 2002; 165(7): 904 - 910. [Abstract] [Full Text] [PDF]

				R. Bals, D. J. Weiner, R. L. Meegalla, F. Accurso, and J. M. Wilson Salt-Independent Abnormality of Antimicrobial Activity in Cystic Fibrosis Airway Surface Fluid Am. J. Respir. Cell Mol. Biol., July 1, 2001; 25(1): 21 - 25. [Abstract] [Full Text] [PDF]

				A. BUSH, H. TIDDENS, and M. SILVERMAN Clinical Implications of Inflammation in Young Children Am. J. Respir. Crit. Care Med., August 1, 2000; 162(2): S11 - 14. [Full Text] [PDF]

				A. BUSH and P. POHUNEK Brush Biopsy and Mucosal Biopsy Am. J. Respir. Crit. Care Med., August 1, 2000; 162(2): S18 - 22. [Full Text] [PDF]

				D. D. Rees, R. A. Rogers, J. Cooley, R. J. Mandle, D. M. Kenney, and E. Remold-O'Donnell Recombinant Human Monocyte/Neutrophil Elastase Inhibitor Protects Rat Lungs against Injury from Cystic Fibrosis Airway Secretions Am. J. Respir. Cell Mol. Biol., January 1, 1999; 20(1): 69 - 78. [Abstract] [Full Text]

				P. M. QUINTON Physiological Basis of Cystic Fibrosis: A Historical Perspective Physiol Rev, January 1, 1999; 79(1): 3 - 22. [Abstract] [Full Text] [PDF]